Form 4: Outlook Therapeutics CFO Buys Shares
Insider Transaction (Form 4)
Lawrence A Kenyon, Chief Financial Officer and a Director of Outlook Therapeutics, Inc., purchased 202,020 shares of common stock on August 14, 2026.
Summary
- Open-market purchase: acquired 101,010 Common Stock on August 14, 2026; holds 106,956 after (Direct).
- Open-market purchase: acquired 101,010 Warrants (right to buy) on August 14, 2026; holds 101,010 after (Direct).
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a bullish signal: an insider made an open-market purchase of $0, committing personal capital to the stock.
Insider Transactions
Lawrence A Kenyon — Director, Officer (Chief Financial Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-14 | Open-market purchase | Common Stock | 101,010 | — | — | 106,956 |
| 2026-08-14 | Open-market purchase | Warrants (right to buy) | 101,010 | — | — | 101,010 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-14 | Open-market purchase (101,010 shares) |
| 2026-08-14 | Open-market purchase (101,010 shares) |
Keywords
insider transaction, Form 4, OTLK, Outlook Therapeutics, Inc., bullish, Lawrence A Kenyon
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.